Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990)

Market Cap	37.62B
Revenue (ttm)	2.02B
Net Income (ttm)	-200.51M
Shares Out	222.84M
EPS (ttm)	-0.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,701
Open	170.50
Previous Close	172.30
Day's Range	169.10 - 177.00
52-Week Range	63.65 - 223.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 26, 2025

About Sichuan Kelun-Biotech Biopharmaceutical

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 1,477
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6990

Financial Performance

In 2023, Sichuan Kelun-Biotech Biopharmaceutical's revenue was 1.54 billion, an increase of 91.62% compared to the previous year's 803.93 million. Losses were -522.21 million, -4.72% less than in 2022.

Financial numbers in CNY